Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Indian Medical Device Certification Scheme To Fill Regulatory Vacuum

This article was originally published in SRA

Executive Summary

A new voluntary scheme is expected to be launched in India on March 15 that will allow private conformity assessment bodies to be approved by the country's national accreditation body so that they may assess and certify the quality management systems and other essential requirements of medical device companies against international standards.

You may also be interested in...



India Can Do More To Align New Medtech Regulations With Global Norms, Says Industry

India will finally get a device-specific regulatory framework when new rules formed by the government come into force next year. While the medtech industry has welcomed this long-awaited development, it hopes that its outstanding concerns will be addressed before the rules come into play.

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules. 

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT040724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel